ADAM10 and Alzheimer disease: A previous secondary analysis by computational identification discloses that miR-103 is estimated to target ADAM10 in AD which is in line with our predicted results, however, the regulated effect of miR-103 on ADAM failed to be validated in our experiment in both two cellular AD models (Augustin et al., 2012).